Tatva Chintan Pharma Chem Limited - Laporan Laba Rugi (TTM)

Tatva Chintan Pharma Chem Limited
IN ˙ NSEI
₹ 996.90 ↓ -40.90 (-3.94%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Tatva Chintan Pharma Chem Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 3,004 3,557 4,192 4,438 4,336 4,152 3,817 3,976 4,236 4,496 4,562 4,198 3,935 3,846 3,714 3,731 3,827 3,941
Change (%) 18.41 17.87 5.86 -2.28 -4.25 -8.07 4.18 6.53 6.13 1.46 -7.98 -6.25 -2.26 -3.43 0.46 2.57 2.98
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,574 1,815 2,029 2,159 2,015 1,813 1,766 1,977 2,327 2,443 2,447 2,143 1,830 1,731 1,874 1,916 2,060 2,003
Change (%) 15.30 11.79 6.44 -6.67 -10.03 -2.59 11.96 17.68 5.00 0.18 -12.44 -14.59 -5.39 8.22 2.24 7.53 -2.76
% of Revenue 52.40 51.02 48.39 48.65 46.47 43.66 46.26 49.72 54.92 54.34 53.65 51.05 46.51 45.02 50.44 51.34 53.82 50.82
Gross Operating Profit 1,430 1,742 2,164 2,279 2,321 2,339 2,051 1,999 1,910 2,053 2,114 2,055 2,105 2,115 1,841 1,816 1,767 1,938
Change (%) 21.84 24.21 5.31 1.88 0.77 -12.32 -2.53 -4.49 7.50 3.00 -2.81 2.45 0.46 -12.96 -1.36 -2.65 9.66
% of Revenue 47.60 48.98 51.61 51.35 53.53 56.34 53.74 50.28 45.08 45.66 46.35 48.95 53.49 54.98 49.56 48.66 46.18 49.18
SG&A 253 279 300 311 320 324 353 377 431 416 483 526 563 552 548 548 545 543
Change (%) 10.67 7.49 3.68 2.61 1.25 9.17 6.62 14.40 -3.50 16.24 8.83 7.05 -1.88 -0.84 -0.01 -0.46 -0.40
% of Revenue 8.41 7.86 7.17 7.02 7.37 7.79 9.25 9.47 10.17 9.25 10.60 12.53 14.31 14.36 14.75 14.68 14.25 13.78
R&D
Change (%)
% of Revenue
OpEx 2,402 2,797 3,141 3,399 3,332 3,267 3,091 3,320 3,651 3,888 3,906 3,653 3,497 3,514 3,517 3,573 3,760 3,852
Change (%) 16.46 12.30 8.20 -1.98 -1.95 -5.38 7.41 9.99 6.48 0.47 -6.47 -4.28 0.48 0.09 1.59 5.24 2.43
% of Revenue 79.96 78.65 74.93 76.59 76.83 78.67 80.97 83.49 86.20 86.48 85.64 87.04 88.87 91.37 94.69 95.76 98.25 97.73
Operating Income 602 759 1,051 1,039 1,005 886 726 656 585 608 655 544 438 332 197 158 67 90
Change (%) 26.18 38.39 -1.14 -3.28 -11.86 -17.99 -9.61 -10.94 3.92 7.83 -16.97 -19.52 -24.15 -40.67 -19.73 -57.75 34.14
% of Revenue 20.04 21.35 25.07 23.41 23.17 21.33 19.03 16.51 13.80 13.52 14.36 12.96 11.13 8.63 5.31 4.24 1.75 2.27
Interest Expense -40 -61 -46 -45 -44 -44 -39 -58 -80 -103 -111 -91 -62 -39 -7 -7 -9 -14
Change (%) 53.88 -25.07 -2.63 -2.75 1.36 -10.50 46.59 38.21 28.37 8.28 -18.06 -32.47 -36.27 -82.22 5.60 21.74 55.02
% of Revenue -1.33 -1.72 -1.10 -1.01 -1.00 -1.06 -1.03 -1.46 -1.89 -2.28 -2.44 -2.17 -1.56 -1.02 -0.19 -0.20 -0.23 -0.35
Net Income 523 687 976 995 959 825 572 460 455 452 459 377 304 261 176 143 57 72
Change (%) 31.45 42.00 1.98 -3.63 -13.92 -30.66 -19.55 -1.20 -0.64 1.48 -17.80 -19.48 -14.15 -32.41 -18.83 -60.04 25.24
% of Revenue 17.40 19.32 23.27 22.42 22.11 19.88 14.99 11.58 10.74 10.05 10.05 8.98 7.71 6.78 4.74 3.83 1.49 1.82

Source: Capital IQ

Other Listings
IN:543321
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista